METOCLOPRAMIDE INTENSOL

Post-LOE

metoclopramide hydrochloride

Pfizer

ANDAORALCONCENTRATE

Approved

Jan 1992

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

METOCLOPRAMIDE INTENSOL (metoclopramide hydrochloride) by Pfizer is clinical pharmacology metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Approved for vomiting associated with emetogenic cancer chemotherapy, postoperative nausea, vomiting in those circumstances where nasogastric suction is undesirable. First approved in 1992.

Drug data last refreshed 1w ago

Mechanism of Action

CLINICAL PHARMACOLOGY Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. Its mode of action is unclear. It seems to sensitize tissues to the action of acetylcholine. The effect of metoclopramide on motility is not…

Worked on METOCLOPRAMIDE INTENSOL at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

METOCLOPRAMIDE INTENSOL

Mechanism of Action

Indications (3)